Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.63 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17547129 | 0.86 | LTA4H (0.64) | LTA4HCYP3A4HSD17B1HSD17B2CYP2C9 | |
| SCHEMBL4677364 | 0.83 | HSD17B1 (0.74) | CYP3A4HSD17B1HSD17B2CYP2C9CYP2D6 | |
| SCHEMBL30956050 | 0.83 | HSD17B1 (0.53) | FFAR4FFAR1CYP3A4HSD17B1HSD17B2 | |
| SCHEMBL30387666 | 0.83 | HSD17B1 (0.57) | FFAR4FFAR1CYP3A4HSD17B1HSD17B2 | |
| SCHEMBL21359337 | 0.82 | HSD17B1 (0.61) | LTA4HCYP3A4HSD17B1HSD17B2CYP2C9 | |
| SCHEMBL7346114 | 0.82 | HSD17B1 (0.61) | FFAR4FFAR1CYP3A4HSD17B1HSD17B2 | |
| SCHEMBL2098031 | 0.82 | LTA4H (0.56) | LTA4HFFAR4FFAR1CYP3A4CYP2C9 | |
| SCHEMBL17081783 | 0.80 | GPR84 (0.60) | LTA4HCYP3A4CYP2C9CYP2D6CYP19A1 | |
| SCHEMBL4674827 | 0.80 | HSD17B1 (0.76) | LTA4HCYP3A4HSD17B1HSD17B2CYP2C9 | |
| SCHEMBL8395055 | 0.80 | NPC1 (0.53) | LTA4HCYP3A4HSD17B1HSD17B2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | LTA4H 3093/4885FFAR4 141/4885FFAR1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.